In Europe, the enhanced safety surveillance (ESS) of seasonal influenza vaccines is mandatory, in order to detect any potential increase in reactogenicity when the vaccine composition is updated. The MF59 ® -adjuvanted influenza vaccine (Fluad™) is the first and the only licensed adjuvanted seasonal influenza vaccine in Europe.
| BACKG ROU N D
The prevention, monitoring, and control of adverse events (AEs) following immunization are essential to ensuring safety and maintaining public confidence in vaccines; without the latter it is almost impossible to achieve optimal vaccination coverage. 1 Post-marketing surveillance is crucial to ensuring the safety profile of a vaccine and identifying reports of unknown AEs. Compared with other vaccines, the pharmacovigilance activities for seasonal influenza vaccines have several distinctive characteristics. For example, the vaccine antigen composition may change twice a year (once for the northern hemisphere and once for the southern hemisphere), large population cohorts of different ages are immunized each year in a pre-defined period of time, and the vaccine market is highly diversified according to national/regional immunization policies. [2] [3] [4] In 2014, the European Medicines Agency (EMA) issued the document "Interim guidance on Enhanced Safety Surveillance (ESS) for seasonal influenza vaccines in the EU". 3 The aim of ESS is to promptly detect any clinically significant change in the frequency and/or severity of expected reactogenic events that can lead to a potentially more serious risk associated with influenza vaccination. 3 Seqirus (formerly Vaccines Novartis Influenza) has implemented the EMA requirement and, starting from the 2015/2016 influenza season, carries out annual ESS of its products available in the EU, including the trivalent seasonal MF59 ® -adjuvanted (Novartis International AG) influenza vaccine (Fluad™, Seqirus Inc).
Fluad™ was first licensed in 1997 in Italy; since then, 81 million doses have been administered worldwide. 5 It is currently authorized for the immunization of people aged 65 years or older in about 30 countries, while in Canada a pediatric formulation indicated for children aged 6-23 months is also available. 6 Moreover, during the last 2009 pandemic, about 100 million doses of MF59 ® -adjuvanted monovalent influenza vaccine were distributed and used in all principal target groups, including children from the age of 6 months and pregnant women. 5 Basically, the MF59 ® adjuvant is a squalene-based oil-in-water emulsion. Squalene is a naturally occurring (also in humans) substance, being a direct pre-cursor of cholesterol. The main purpose of including the MF59 ® adjuvant is to enhance vaccine immunogenicity, which is particularly important in older adults, who are usually poorly responsive to traditional vaccines owing to immunosenescence. 5, 7 Indeed, numerous [8] [9] [10] [11] [12] [13] randomized controlled immunogenicity trials have shown that, compared with unadjuvanted formulations, Fluad™ induces significantly higher antibody titers against both homologous and heterologous virus strains, as well as higher seroconversion and seroprotection rates. Several cohort and case-control studies [14] [15] [16] [17] [18] have documented a higher in-field effectiveness of Fluad™ vs unadjuvanted vaccines in reducing the number of laboratory-confirmed influenza cases, hospitalizations for pneumonia and/or influenza, acute cardiovascular and cerebrovascular events and influenza-like illness. [14] [15] [16] [17] [18] [19] The safety and tolerability profile of Fluad™ is well-established.
An integrated analysis of 64 clinical trials 20 revealed that people immunized with MF59 ® -adjuvanted vaccines, in comparison with unadjuvanted vaccines, had a significantly lower risk of unsolicited AEs. Indeed, in the overall population, reports of any unsolicited AEs decreased by 35% [adjusted risk ratio, adjuvanted vs unadjuvanted: 0.65 (95% CI: 0.60-0.70)]. With regard to solicited AEs, these were reported more frequently in subjects immunized with adjuvanted formulations than in those who received non-adjuvanted vaccine.
However, most of these AEs involved the injection site were of mild/ moderate intensity and resolved in a few days. 20 In a 3-year prospective cohort study 21 The secondary objective was to compare the observed frequencies between seasons.
| ME THODS

| Enhanced passive safety surveillance (EPSS)
The Interim guidance document 3 specifies three options for ESS: 
| Surveillance design and setting
The EPSS protocols complied with the Interim guidelines. 3 The study was non-interventional, since the decision to utilize a given vaccine was a part of routine care and was left entirely to the discre- The surveillance activities were planned to include a total of 1000 routine exposures to Fluad™. According to the summary of product characteristics (SPC), 23 Fluad™ should be administered to subjects aged ≥65 years.
Following routine vaccination, GPs and their staff instructed vaccinees to report any AE in general, and specifically those occurring in the first 7 days. A standardized and uniquely numbered vaccination card with specific information on the batch, brand, date of vaccine administration, and the contact number for reporting spontaneous AEs was issued to vaccinees. Vaccinees were also informed that they could report AEs either by phoning the call center or directly to the health authorities, as indicated on the vaccination card.
| Data collection, review, and analysis
All spontaneous individual case safety reports (ICSRs) of AEs were collected and processed by the trained staff of a toll-free call center through a structured interview. In particular, the following information was systematically gathered: description of the events experienced, chronology of events, severity, outcome as well as demographics, medical history, ongoing health conditions, and concomitant vaccination/medications. The reports included the vaccination card number to enable identification of the spontaneous AEs which originated from the same sample population which was the denominator of the surveillance. Multiple contacts with the call center for the same vaccination card number (either for reports of different AEs or of the same event reported by different reporters) were handled as a separate ICSR with its own unique reference number. The total number of Fluad™ doses administered was collected directly from GPs.
Reports of spontaneous AEs received at the call center were entered in an electronic safety report capture tool. All AEs were promptly translated and encoded by the call center staff using the medical dictionary for regulatory activities (MedDRA ® ) of the ongoing version at the time of the surveillance. Each report was assigned a unique reference number.
To be considered eligible spontaneous AEs had to be reported to the call center as a part of EPSS and to meet the following criteria of a valid report: ≥1 identifiable reporter, ≥1 identifiable vaccinee, ≥1 suspected adverse reaction, and ≥1 suspected medicinal product (suspected vaccine product). Moreover, ICSRs that occurred beyond 7 days following vaccination were out of scope of the EPSS (and therefore were not included in the current analysis) but were included in the continuous routine evaluation of safety data in the global safety database. All eligible AEs were reviewed on a weekly basis.
| Data analysis
The primary outcome was the number of ICSRs per 100 doses administered, that is the ICSR reporting rate (%). The denominator cor- and injection site reactions (including pain, erythema, and swelling).
rAEIs were also described according to seriousness (serious and nonserious) and their observed reporting rates were compared with the expected rates as per the SPC of Fluad™. 24 Subsequently, AEs constituting risk for risk management plan (RMP) were described and analyzed; the following AEs were considered: anaphylaxis, extensive limb swelling, convulsions, neuritis, encephalitis, vasculitis, Guillain-Barré syndrome, demyelination disorders, Bell's palsy, immune thrombocytopenia, hemolytic disorders, and vaccination failure. Finally, other spontaneous AEs and the off-label use of Fluad™ (ie, vaccine administration to subjects < 65 years) were also described.
All data were described separately for each influenza season.
Data were reported in absolute and relative (%) numbers with 95% confidence intervals (CIs) computed by means of the exact method.
Fisher's exact test was used to compare the reporting rates across seasons.
| Ethics statement
The study was conducted in full accordance with good pharmacovigilance practices. 25 As required, the study protocol was submitted annually to the Ethics Committee of the Liguria Region (Genoa, Italy) and was approved.
| RE SULTS
| Overall exposure data
In the three seasons, the study was carried out mainly in the month 
| Analysis of individual case safety reports (ICSRs)
A total of 5 (0.5%; 95% CI: 0.2%-1.1%), 7 (0.7%; 95% CI: 0.3%-1.4%), and 5 (0.5%; 95% CI: 0.2%-1.1%) ICSRs were received in seasons 2015/2016, 2016/2017, and 2017/2018, respectively. No betweenseason variation in the reporting rate was observed (P = .83). The ICSRs analyzed contained a total of 9 (0.8%; 95% CI: 0.4%-1.6%), 18
(1.7%; 95% CI: 1.0%-2.7%), and 12 (1.1%; 95% CI: 0.6%-2.0%) AEs 
| Analysis of reactogenic adverse events of interest (rAEIs)
As shown in Table 1 , a total of 22 rAEIs [3 (0.3%; 95% CI: 0.1%-0.8%), 12 (1.1%; 95% CI: 0.6%-2.0%), and 7 (0.7%; 95% CI: 0.3%-1.4%) rAEIs in influenza seasons 2015/2016, 2016/2017, and 2017/2018, respectively] were reported, with non-significant differences between seasons (P = .058). The observed frequency was lower than expected on the basis of the known safety profile of the product.
A large overlap of the exact 95% CIs of the reporting rates of single rAEIs suggested no between-season variation. Across the three seasons, only one rAEI was classified a serious: a case of headache reported in the 2016/2017 season (described above).
| Analysis of reports per adverse event defined as risk in the risk management plan (RMP)
Across the three seasons, one AE was identified as risk per RMP. This was a case of extensive limb swelling reported in the 2016/2017 season.
Specifically, a 68-year-old vaccinee developed injection site swelling, pain, and erythema on the same day as vaccination with Fluad™. A topical heparinoid was applied, but the AEs at the time of the report were still not resolved. This ICSR contained the preferred term "injection site swelling", which is used to identify potential cases of extensive limb swelling, an identified risk of Fluad™ according to the RMP. However, review of the narrative did not indicate any extensive or large swelling, or peripheral swelling crossing of the joints of the limb involved. Hence, identification of this risk is limited to the preferred term and is not clinically consistent with extensive limb swelling. 
| Analysis of other spontaneous adverse events and off-label use
| D ISCUSS I ON
This report is the first to provide an overview of spontaneous ICSRs received from vaccinees with Fluad™ in three consecutive influenza seasons in the context of EPSS. The observed overall safety profile of Fluad™ proved to be consistent with the currently known safety profile of the product. No clinically relevant safety information (due to unexpected spontaneous reporting frequency, intensity, or nature of events) that had not been previously identified through routine post-marketing surveillance emerged. Only two ICSRs involved at least one AE that was assessed as serious. Despite the temporal relationship, there was no sufficient evidence to link these adverse events with Fluad™ administration.
Overall, EPSS may be a useful approach to support the early detection of possible safety changes in a near real-time modality; this has been previously documented by EPSS of a trivalent split virion inactivated influenza vaccine (Vaxigrip™, Sanofi Pasteur) and an intradermal trivalent split virion inactivated 15 µg (Intanza™ 15 µg, Sanofi Pasteur) vaccine. 24, 25 Our well-established EPSS of Fluad™ will therefore continue in the next influenza season.
The present study has both strengths and limitations. A particular strength lies in the fact that the population was homogeneous, which enabled us to make a direct between-season comparison. In all three seasons, EPSS was conducted in Italy by the same GPs, who monitored the same population in almost the same period (ie, close to the start of the national immunization campaign and before the peak of disease). Furthermore, vaccine recommendations remained unchanged during the study period. Indeed, it is known that AE reporting rates may differ both temporally 26 and geographically. 26, 27 Italy was chosen as a reference country since Fluad™ is one of the oldest brands available in this country and, at the time of the study, had a very high market share in subjects aged ≥65 years. This latter fact also enabled us to reach a target population size of 1000 doses relatively quickly and efficiently. Furthermore, rigorous quality control and the use of vaccination cards enabled us to identify/attribute data unambiguously, thus minimizing the risk of misclassification.
The study limitations are basically inherent in the nature of passive surveillance activities. First, the spontaneous reporting of AEs may result both in under-reporting (whereby only a fraction of the total number of AEs occurring after vaccination are reported) and in differential reporting (whereby more serious AEs and those with a shorter onset time after vaccination are more likely to be reported during the surveillance period than minor AEs or those with a longer time to onset). Second, owing to the short-term nature of the EPSS, it may be difficult to accurately estimate the rates of certain potential/identified risks per RMP that are rare, more complex to diagnose, of multifactorial etiology, and/or exhibit long latency.
We believe that these data are of primary importance to stakeholders in countries where Fluad™ is authorized. Moreover, considering the recent preferential recommendations on the use of Fluad™ in subjects aged ≥65 and ≥75 years issued by Public Health England 28 and the Italian Ministry of Health, 29 respectively, we may expect a significantly larger population to be vaccinated with Fluad™ in the upcoming influenza seasons. For instance, Fluad™ will be used preferentially in the UK in all over 65-year olds 29 ; this means that the number of doses administered is likely to rise from zero to approximately 9-10 million (assuming a vaccination coverage of 75% 30 among the 11.8 million people aged ≥65 years 31 ). The present report will therefore be very useful in these jurisdictions.
To conclude, Fluad™ is the first, and currently the only, available seasonal influenza vaccine in Europe that has been specifically designed to overcome immunosenescence, a phenomenon affecting older adults. Our analyses confirmed that the safety data that emerged from passive ESS over three consecutive seasons were consistent with the known safety profile of Fluad™, which has been amply established over the last 20 years. Indeed, no significant changes in the safety profile of Fluad™ were observed.
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